Information released on next wave of price disclosure cuts, as the potential impact of a new PBS bill is revealed
The latest round of price disclosure cuts – to be effective in April – have been released by the PBS.
Among the medicines to be impacted in the April 2018 price disclosure reduction cycle are:
- Candesartan – various oral formulations to drop by 13.75%
- Candesartan with hydrochlorothiazide – to drop by 12.52%
- Celecoxib 100 & 200 mg tablets – down by 18.90%
- Esomeprazole 20 & 40mg tablets and capsules – to drop by 42.46%
- Fentanyl transdermal patches – down 13.04%
- Naloxone injections – 26.37%
- Olanzapine tablets and wafers in a range of sizes – down by 22.85%
- Rosuvastatin – dropping by 23.03%
- Sildenafil 20mg – down by 20.46%
- Telmisartan 40 & 80mg – to drop by 34.04%
- Telmisartan with hydrochlorothiazide – down by 14.51%
- Zoledronic Acid – down by 29.12%
The TGA provided an additional table with the release to show how the price disclosure outcome will change should current proposed amendments to the National Health Amendment (Pharmaceutical Benefits—Budget and Other Measures) Bill 2017) , are passed by Parliament.
This bill includes a change to a 30% ‘unadjusted price reduction’ in certain circumstances.
The bill, introduced to parliament in October 2017, will increase the current statutory price reduction that applies when the first new brand of an existing pharmaceutical item is listed on the PBS, as well as extend and introduce statutory price reductions applying on certain anniversaries of an F1 formulary drug being listed on the PBS; introduce ministerial discretion in relation to the application of statutory price reductions in certain circumstances; and, make minor amendments to price disclosure arrangements.
Click here to see the full lists of impacted medicines.